We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Advanced Prostate Cancer
Center of Excellence
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Prostate Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Prostate Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
No comments yet, be the first to start the discussion!
Charles Maack
Mar 24, 2022
#5 - in view of STEMI leuprolide/ADT would be a concern. As an initial alternative I would recommend check testosterone (T) level to ascertain threat. Check prolactin level and if 5 or over, reduce with cabergoline.. Start dutasteride/Avodart to inhibit any T presence converting to DHT. Monitor closely to see if PSA level subsides. Any use of ADT would require very close monitoring and likely lower doses than usually prescribed.
stephen vaughan
Mar 25, 2022
2
Alfonso Rivera
Mar 25, 2022
# 3
Jaime Lozano
Mar 25, 2022
It is important to look at the original pathology in order to be able to make the right decision on his current treatment. What was the original Gleason score? Pathologic staging? Seminal vesicle invasion? Extracapsular extension? Positive pelvic nodes? PSA post op? What does the rectal exam show now? The answer to these questions will guide us to the proper management. PSA 7.5 ng/ml is a very high level for a post prostatectomy patient. He must have gross disease somewhere.
Fabio Almeida
Mar 25, 2022
#5#4
Assuming the PET study that was done was a FDG which is typically not helpful for PCa.
- Consider PSMA PET/CT for accurate re-staging. With a PSA of 7.5ng/mL unlikely that a PSMA imaging study would be negative. The rapid PSAdT is concerning for bony mets, but recurrence limited to the pelvic soft tissues still in the 20-40% range. He may have options for focal or pelvic salvage radiotherapy.
- Consider relugolix for ADT as this has a better CVD profile compared to Lupron (this should actually be the new SOC for ADT)
- Consider secondary hormonal treatment with bicalutamide (or similar next generation versions enzalutamide, darolutamide, apalutamide)
pamela bayer
Mar 25, 2022
5- would run a PSMA/Pet to see if possible treatment alternatives with radiation or PSMA Lu and to determine where the tumors are located. Need risk assessment. Too high risk for ADT with heart condition, Regulorix has the least cardio toxic effect if determine need some ADT treatment.
Charles Maack
Mar 25, 2022
Where am I missing the comments regarding a supposed #10? Provided status mentioned "PET/CT with no definite evidence of metastatic disease." What form of PET/CT? #5 continues for me. This man's condition of STEMI requires careful consideration as to treatment with radiation or chemo since either can have an effect on heart issues
Fabio Almeida
Mar 25, 2022
There is an error on formatting of these posts. If you add a line return it is adding "
" - so to be ignored
edgard ramirez
Mar 31, 2022
Debe re-estadificarse. Practicarle un psma-pet/ct o rm.Si no se dispone de este examen,practicar imagenes convencionales (Gammagrafia osea,TC Abdominopelvico y TC Torax)
y de acuerdo a los resultados se toma la decision terapeutica
Marko Vukovic
Apr 01, 2022
I would measure testosteron level, repeat PSA and PSAM-PET CT in one month. Although the patient developed BCR for sure, he may develop castration resistance in the mean time (no date of follow up between 2016 and 2019, so he may developed BCR way before 2019). In that case, it would be reasonable to start with Enzalutamid (if no mets were detected on PSMA-PET)
Charles Maack
Apr 01, 2022
Any chance we can be provided the actual treatment that ensued and results? We provide our opinions but have no idea how reasonable they are/were.
Prasanta Kumar Pradhan
Apr 03, 2022
Qualifying PET scan is essential.PSMA PET is required for staging the disease status.However,if FDG PET/CT scan has been done and negative ,then its an advantage and may predict the prognosis.
i am sure PSMA PET will be positive with the current level of PSA
I would suggest local salvage radiotherapy with ADT for at least two years.
Muhammad Bulbul
Apr 17, 2022
It is important to examine the pathology for Gl score, PSM, SVI..., Our practice is to do PET PSMA. It is unusual with a PSA of 7.5 not to see anything on PET PSMA, we are encountering it it with BCR ; PSA under 1.0. Yet our approach to these with documented BCR and short doubling time is a short course of ADT (6 months) and EBRT.
Ramon Caballero
Sep 21, 2022
PSMA PET Relugolix NHA. While not in guidelines there is evidence for apalutamide (3Presto).
Nov 17, 2024
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.
Charles Maack
Mar 24, 2022
stephen vaughan
Mar 25, 2022
Alfonso Rivera
Mar 25, 2022
Jaime Lozano
Mar 25, 2022
Fabio Almeida
Mar 25, 2022
pamela bayer
Mar 25, 2022
Charles Maack
Mar 25, 2022
Fabio Almeida
Mar 25, 2022
edgard ramirez
Mar 31, 2022
Marko Vukovic
Apr 01, 2022
Charles Maack
Apr 01, 2022
Prasanta Kumar Pradhan
Apr 03, 2022
Khoury Elie
Apr 03, 2022
Swapan Kumar Nath
Apr 12, 2022
Muhammad Bulbul
Apr 17, 2022
Ramon Caballero
Sep 21, 2022
Nov 17, 2024
Pending Moderator approval.